The Distinguished Achievement in Proteomic Sciences Award recognizes a scientist for distinguished scientific achievements in the field of proteomic science. This award is sponsored by the Journal of Proteome Research - ACS Publications.
Shared by two recipients. Please click on the photos below to learn more about the award winners.
United States
China
Dr. Karin Rodland’s many achievements include her decades long commitment to the application of cutting-edge mass spectrometry technologies to compelling biological problems. She has provided biological focus to the proteomics group at PNNL since 2002, insuring that the technologies were applied to the most significant biomedical problems and that issues of experimental design and data analysis reflected the needs of the biomedical community. Dr. Rodland has published extensively in the field of proteomics, on the use of mass spectrometry to further understanding of basic biological processes. She was among the first to characterize the role of the G-protein coupled calcium-sensing receptor in modulating proliferation-associated signal transduction pathways. However, her impact can be better quantified in terms of her unique ability to establish collaborations that bring cutting-edge proteomics technologies into the translational cancer medicine space through the application of proteogenomics to understand drug response and therapeutic resistance.
Dr. He is the leading scientist studying proteomics in China and liver proteomics in the world. He was the founder of Chinese arm of HUPO (CNHUPO) and among the first group of people who founded HUPO in 2001. He was the first Chinese scientist who led an international consortium- Human Liver Proteome Project (HLPP), and the founder of Beijing Proteome Research Center, Phoenix Center (proteomics) and Institutes of Biomedical Sciences Fudan University. The past 21 years have witnessed his great contributions and impact to the field of proteomics. He initiated over 10 programs of proteomics research in China, successfully organized 13 international and national proteomics conferences and over 30 training courses, including the 3rd HUPO Congress, the 6th AOHUPO Congress and Nature Conference: Life science in the age of big data, which greatly promoted proteomics research in China and beyond. Through his tireless efforts, China now is a power house in the area of proteomics and has contributed significantly the global landscapes of proteomics.
The Discovery in Proteomic Sciences Award recognizes a scientist for a single discovery in the field of proteomics. This award is sponsored by Journal of Proteomics - ELSEVIER BV.
Shared by two recipients. Please click on the photos below to learn more about the award winners.
Ireland
United States
Dr. Ben Collins is among the most prominent members of a rapidly growing research community that have transformed DIA from an attractive conceptual curiosity into the robust, benchmarked and widely used technique.
Ben’s advances include:
The improvements in data quality and robustness enabled by DIA are now driving the adoption of proteomic approaches more broadly in life sciences and will continue to do so as further developments are made. Ben has played a major role in this process both from the technology development and application perspectives.
Mentoring Session 2: Career, Family and Work-Life Balance
Benjamin A. Garcia obtained his BS in Chemistry at UC Davis in 2000, where he worked as an undergraduate researcher in Prof. Carlito Lebrilla’s laboratory. He then received his PhD in Chemistry in 2005 at the University of Virginia under Prof. Donald Hunt and then was an NIH NRSA Postdoctoral Fellow at the University of Illinois under Prof. Neil Kelleher from 2005-2008. From there Ben was appointed as an Assistant Professor in the Molecular Biology Department at Princeton University from 2008-2012, until his recruitment as the Presidential Associate Professor of Biochemistry and Biophysics at the University of Pennsylvania Perelman School of Medicine in 2012, and was promoted to full Professor in 2016, and named the John McCrea Dickson M.D. Presidential Professor in 2018. The Garcia lab has been developing and applying novel proteomic approaches and bioinformatics for interrogating protein modifications, especially those involved in epigenetic mechanisms such as histones during human disease, publishing over 310 publications. Dr. Garcia is on the editorial boards for the Molecular Omics and Molecular and Cellular Proteomics journals, and serves on the Board of Directors for the U.S. Human Proteome Organization (HUPO) and the World HUPO Council. He has also been recognized with many honors and awards for his mass spectrometry research including the American Society for Mass Spectrometry (ASMS) Research Award, a National Science Foundation early faculty CAREER award, an NIH Director’s New Innovator Award, the Presidential Early Career Award for Scientists and Engineers (awarded by President Obama), an Alfred P. Sloan Fellowship, the PITTCON Achievement Award, the American Chemical Society Arthur F. Findeis Award for Achievements by a Young Analytical Scientist, inducted into the Royal Society of Chemistry, the ASMS Biemann Medal and most recently the HUPO Discovery in Proteomic Sciences Award.
This award recognizes a scientist in the field of clinical and translational proteomics and is sponsored by Clinical Proteomics - BioMed Central. Please click on the photo to learn more about this award winner.
Japan
Dr. Tadashi Yamamoto is a pioneer of proteomics of kidney diseases and urine biomarker discovery since he engaged in the HUPO Human Kidney & Urine Proteome Project (HKUPP) as the chair in 2005 and contributed in a major way to the introduction of proteomics in nephrology. During his chairmanship for about 10 years, the HKUPP provided the HKUPP guide for urine sample collection for urine proteomics and collected proteome datasets of urine, kidney and urinary tract organ through international collaborations. Dr. Yamamoto and his colleagues have developed protocols for proteomics of formalin-fixed paraffin-embedded human kidney biopsy tissues and analyzed chronic kidney disease (CKD) with glomerular sections collected by a laser micro-dissection system to understand protein interactions in the glomerulus by proteomics. Dr. Yamamoto is now expanding this approach to discover biomarkers for other diseases, such as diabetes and its complication and cancers by establishing urinary native peptide separation and label-free peptidomics as well. The proteomic analysis of patient kidney biopsy samples introduced by Dr. Yamamoto opened new insights into kidney tissue injury and reactions, which are not easily evaluated by regular pathological examination. The individual biopsy tissue proteomics will help understand disease conditions more precisely than histology and will contribute to precision medicine of CKD patients. In addition, the discovery of urine biomarkers for kidney segment-specific injuries will not only contribute to individual CKD patient care by the precise recognition of kidney injuries but also to facilitate development of new treatments for CKD, which have not achieved yet, by providing the urine biomarkers for evaluation of efficiency of new treatments. Dr. Yamamoto is developing a proteomics assay systems in clinical laboratories for evaluation of hundreds of urinary biomarkers at once and has already achieved a throughput to analyze more than one thousand proteins in individual urine sample at a speed of ~50 analyses a day. Such proteomics systems may be used as a general laboratory equipment in the future for quantitation of multiple disease markers in urine since it does not need to develop antibodies as immunoassay.
The Science and Technology Award recognizes an individual or team in private industry who played a key role in commercialization of a proteomics technology, product, or procedure. The emphasis for the award is on making the technology, product, or procedure widely available, which is different from the basic scientific invention. This award is sponsored by the HUPO Industry Advisory Board. This award is shared by two recipients. Please click on the photos below to learn more about the award winners.
Bruker Daltonics Inc.
Bruker Daltonics Inc.
Mel Park and Oliver Raether are recognized for the commercialization of the Trapped Ion Mobility Spectrometry (TIMS) Parallel Accumulation Serial Fragment (PASEF) method which takes advantage of the unique features of the TIMS device to improve MS/MS sequencing speed and sensitivity on QTOF Instruments. TIMS was developed as a compact and convenient way to perform true ion mobility measurements using an electric field gradient to trap ions in a flowing gas. A 5 cm TIMS device achieves the same resolution as a 2-meter-long drift tube ion mobility system, without the high voltages and ion losses. Coupling the TimsTOF PASEF method is transformative with the combination of increased MS/MS speed with improved sensitivity is helping to revolutionize the field of proteomics improving proteome coverage and sample throughput such as studies of large clinical cohorts, e.g; plasma proteomics or urine proteomics. High sensitivity proteomics for single cell, immunopeptidomics and proteomics of tissue biopsies, label free quantitation, SILAC, DIA and PRM proteomics are all applicable to the TimsTOF PASEF instrument.
Mel Park and Oliver Raether are recognized for the commercialization of the Trapped Ion Mobility Spectrometry (TIMS) Parallel Accumulation Serial Fragment (PASEF) method which takes advantage of the unique features of the TIMS device to improve MS/MS sequencing speed and sensitivity on QTOF Instruments. TIMS was developed as a compact and convenient way to perform true ion mobility measurements using an electric field gradient to trap ions in a flowing gas. A 5 cm TIMS device achieves the same resolution as a 2-meter-long drift tube ion mobility system, without the high voltages and ion losses. Coupling the TimsTOF PASEF method is transformative with the combination of increased MS/MS speed with improved sensitivity is helping to revolutionize the field of proteomics improving proteome coverage and sample throughput such as studies of large clinical cohorts, e.g; plasma proteomics or urine proteomics. High sensitivity proteomics for single cell, immunopeptidomics and proteomics of tissue biopsies, label free quantitation, SILAC, DIA and PRM proteomics are all applicable to the TimsTOF PASEF instrument.
